FindTrial
Sign In

Study on prediction of the efficacy of PARP inhibitors by homologous recombination repair defects and gene reversion in prostate cancer

Study on prediction of the efficacy of PARP inhibitors by homologous recombination repair defects and gene reversion in prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035942
Enrollment
Unknown
Registered
2020-08-20
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Case series:PARP inhibitors

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Histologically confirmed diagnosis of prostate cancer; 3. Documented evidence of metastatic castration resistant prostate cancer (mCRPC) according to the EAU guideline 2020 version; 4. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC; 5. Radiographic or PSA progression at study entry; 6. Qualifying germline HRR mutation, HRR genes include BRCA1/2.

Exclusion criteria

Exclusion criteria: 1. Any previous treatment with PARP inhibitor, including olaparib; 2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy; 3. Other malignancy; 4. Subjects with known brain metastases.

Design outcomes

Primary

MeasureTime frame
radiographic progression free survival;—

Secondary

MeasureTime frame
objective response rate;PSA progression free survival;overall survival;—

Contacts

Public ContactYao Zhu

Fudan university Shanghai Cancer Center

yaozhu09@fudan.edu.cn+86 13816751347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026